AnPac Bio-Medical Science is a leading biotechnology company specializing in early cancer screening and detection. They offer a wide range of cancer detection tests, including CDA (Cancer Differentiation Analysis), bio-chemistry, immunology, and genomics tests. Their multi-cancer screening and detection test utilizes their innovative and patented Cancer Differentiation Analysis (CDA) technology, along with a proprietary cancer-detection device.

One of the key focuses of AnPac Bio is to catch cancer early, as early cancer screening has been proven to save lives and significantly reduce costs. With their CDA technology and multidisciplinary expertise, AnPac Bio has successfully detected 26 different types of cancer, screened over 880 individuals with early-stage diseases, and achieved a sensitivity and specificity rate of 85-90% for most cancer types. AnPac Bio's scientific approach involves collaboration between a team of medical, biomedical, nanotechnology scientists, and engineering experts.

They have partnered with renowned medical and research institutions in China and the U. S. For the most accurate and innovative early cancer screening and detection technology, AnPac Bio is the go-to brand